Company Profile
Wave Life Sciences Stock Price, News & Analysis
- Ticker:
- WVE
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
6.02 USD (+1.52%)
Close
Last updated: August 6, 2026
1.09B USD
Market cap
Why the stock is moving
The latest company update was “Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware”. WVE changed 1.52% and closed at $6.02 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
RNA Medicines Platform Company
Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines across both rare and common diseases. Its PRISM platform combines RNA-targeting modalities, chemistry innovation, and human genetics to design medicines that can address disease biology through RNAi and RNA editing.
Obesity and Cardiometabolic Program
WVE-007 is an investigational GalNAc-siRNA targeting INHBE for obesity and related cardiometabolic disease. The program is designed to induce fat loss without muscle loss and is distinct from incretin-based approaches. Phase 1 data have shown fat reduction, visceral fat reduction, waist-circumference effects, and muscle preservation, supporting evaluation in higher-BMI populations and broader metabolic settings.
RNA Editing in Liver and Rare Disease
WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency. Clinical data from RestorAATion-2 support the potential to address both lung and liver manifestations by reducing mutant Z-AAT protein and increasing wild-type M-AAT protein. WVE-008 extends the RNA editing approach into PNPLA3 I148M liver disease.
Strategic Position
Wave is best understood as an RNA medicines company trying to prove that its chemistry and modality breadth can support both high-prevalence diseases such as obesity and genetically defined liver diseases. Its value depends on clinical translation across WVE-007, WVE-006, and WVE-008, with additional optionality in Huntington's disease and Duchenne muscular dystrophy.
Future catalysts
Additional Phase 1 INLIGHT data for WVE-007 in the second half of 2026.
Phase 2a multidose INLIGHT data over the 12-month assessment period.
Initiation of WVE-007 Phase 2 trials in incretin combination and post-incretin maintenance settings in the second half of 2026.
FDA meeting on a potential accelerated approval pathway for WVE-006 by the end of summer 2026.
WVE-006 600 mg monthly multidose data in the second half of 2026.
CTA filing for WVE-008 in PNPLA3 liver disease in the second half of 2026.
Recent news
- 01
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Source: Wave Life Sciences
- 02
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Wave Life Sciences
- 03
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
Source: Wave Life Sciences
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Wave Life Sciences (WVE)?
Wave Life Sciences (WVE) most recently closed at 6.02 USD, a +1.52% move versus the previous session.
What is the market cap of Wave Life Sciences (WVE)?
Wave Life Sciences currently has a market capitalization of 1.09B USD on BioPharmSignal.
What does Wave Life Sciences do?
RNA Medicines Platform Company Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines across both rare and common diseases. Its PRISM platform combines RNA-targeting modalities, chemistry innovation, and human genetics to design medicines that can address disease biology through RNAi and RNA editing. Obesity and...
On which exchange is WVE stock listed?
Wave Life Sciences (WVE) is associated with NASDAQ, United States, Life Science Tools.
What is WVE-007?
Additional Phase 1 INLIGHT data for WVE-007 in the second half of 2026.
Which conditions is Wave Life Sciences targeting with WVE-007?
Wave Life Sciences is associated with rare disease, metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Wave Life Sciences describe recent progress with WVE-007?
Additional Phase 1 INLIGHT data for WVE-007 in the second half of 2026.
What is WVE-006?
RNA Editing in Liver and Rare Disease WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency.